SRX Global Inc. (SRXH) has entered into a definitive Stock Purchase Agreement to acquire CERo Therapeutics, Inc., the wholly-owned operating subsidiary of CERo Therapeutics Holdings, Inc. The transaction will make CERo Therapeutics a wholly-owned subsidiary of SRX Global.
Key Details
- Agreement Date: October 6, 2026.
- Transaction Consideration: SRX Global will (i) issue $1,000,000 in SRXH common stock, (ii) forgive and cancel all obligations under a promissory note with an outstanding principal balance of $8,249,643.77, and (iii) assume approximately $1,562,000 in specified liabilities.
- Go-Shop Provision: The agreement includes a 30-day "go-shop" period, allowing CERo Therapeutics Holdings to solicit alternative acquisition proposals. A reciprocal termination fee of $750,000 is payable by either party under certain conditions.
- Closing Conditions: The deal is subject to customary closing conditions, including SRX's acquisition of certain series of the seller's preferred stock and obtaining necessary waivers from other preferred stockholders.